Skip to content
Homepage
Author:
Transgene S.A.
Posted Date:
June 24, 2026
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Transgene S.A.
June 24, 2026
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
Transgene S.A.
June 21, 2026
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Transgene S.A.
May 25, 2026
Transgene’s Combined General Meeting of May 22, 2026
Transgene S.A.
May 22, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
Transgene S.A.
May 4, 2026
1
2
3
Next
